September 29, 2015
2 min read
Save

Lymphoma & Myeloma 2015 to highlight advances in basic science, translational medicine

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies will be held Oct. 22-24 at the Waldorf Astoria in New York.

HemOnc Today will serve as a media partner for the congress, which focuses on the latest advances in lymphoma, myeloma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia and other plasma cell neoplasms.

Morton Coleman, MD

Morton Coleman

The meeting — launched in 2000 — is the largest of its kind in the United States, attracting more than 1,000 clinicians.

“This is the premier meeting for clinicians in these specialties,” congress chair Morton Coleman, MD, director of the Center for Lymphoma and Myeloma at NewYork Presbyterian Hospital-Weill Cornell Medical Center and clinical professor of medicine at Weill Cornell Medical College, told HemOnc Today. “The common refrain I hear from attendees is, ‘I don’t need to go to ASH or ASCO anymore and run from room to room. You have everything right here for us in one place.”

The agenda — which features lectures, debates and panel discussions — is designed to explore developments in clinical trials, basic science and translational medicine.

“When you walk out of here, you’re as up to date as you can possibly be,” Coleman said. “We cover everything.”

Program highlights include lectures that will explore immune approaches to Hodgkin’s disease and the integration of signaling inhibitors into practice for chronic lymphocytic leukemia.

One of the myeloma sessions will culminate with a debate about whether HDAC inhibitors represent a meaningful advance in myeloma treatment or simply a more toxic therapy.

This year’s faculty includes more than 40 leaders in clinical and translational research, pathology, immunology and molecular biology.

Congress co-chairs are John P. Leonard, MD, Ruben Niesvizky, MD, and Richard R. Furman, MD, all of Weill Cornell Medical College and NewYork Presbyterian Hospital/Weill Cornell Medical Center.

Other faculty members include Kenneth C. Anderson, MD, Jennifer R. Brown, MD, PhD, Paul Richardson, MD, and Margaret A. Shipp, MD, all of Dana-Farber Cancer Institute; Stephen M. Ansell, MD, PhD, James R. Berenson, MD, and Joseph Mikhael, MD, all of Mayo Clinic; Jonathan Friedberg, MD, of University of Rochester; Allison J. Moskowitz, MD, of Memorial Sloan Kettering Cancer Center; Antonio Palumbo, MD, of University of Torino in Italy; Kanti R. Rai, MD, of Hofstra Northshore-LIJ School of Medicine; and Laurie H. Sehn, MD, of University of British Columbia.

“The faculty is second to none,” Coleman said. “I vet the faculty not only for their expertise, but for their ability to present. The quality is just outstanding. We have all the heavyweights in these fields — you name them, they’ll be there.”

For more information about the meeting:

Call (800) 233-0957 or go to www.imedex.com/lymphoma-myeloma-conference/index.asp.